Study Comparing the MiStent SES Versus the XIENCE EES Stent (DESSOLVE III)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02385279 |
Recruitment Status : Unknown
Verified December 2020 by ECRI bv.
Recruitment status was: Active, not recruiting
First Posted : March 11, 2015
Last Update Posted : December 19, 2020
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Stenosis | Device: MiStent Device: XIENCE EES | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1404 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries |
Actual Study Start Date : | March 20, 2015 |
Actual Primary Completion Date : | January 31, 2017 |
Estimated Study Completion Date : | January 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: MiStent®
Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
|
Device: MiStent
Percutaneous Coronary Intervention |
Active Comparator: XIENCE EES
Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
|
Device: XIENCE EES
Percutaneous Coronary Intervention |
- Non inferiority comparison of a device oriented composite endpoint (DOCE) or Target Lesion Failure (TLF) of the MISTENT group to the XIENCE group [ Time Frame: 12 months postprocedure ]TLF is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically-indicated target lesion revascularization.
- POCE defined as all-cause death, any Myocardial Infarction (MI), or any revascularization [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
- MACE defined as all-cause death, any MI, or any Target Vessel Revascularization (TVR) [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
- Target Vessel Failure (TVF) defined as cardiac death, TV MI, or clinically indicated TVR [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
- DOCE/TLF defined as cardiac death, TV MI or clinically indicated Target Lesion Revascularization (TLR) [ Time Frame: 30 days, 6 months, 2 years, 3 years ]
- Mortality [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
- Myocardial infarction [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
- Revascularization [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
- Stent thrombosis rates according to ARC classification [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All comers" patients:
- Male or female patients 18 years or older;
- Presence of one or more coronary artery stenoses of 50% or more in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation.
- The vessel should have a reference vessel diameter ranging from 2.5 mm to 3.75 mm (no limitation on the number of treated lesions, vessels, or lesion length); All lesions of the patient must comply with the angiographic inclusion criteria.
- The patient is judged to be capable of providing voluntary informed consent and has been fully informed of the nature of the study, is willing to comply with all study requirements and will provide written informed consent as approved by the Ethics Committee of the respective clinical site.
Exclusion Criteria:
- Known pregnancy or breastfeeding at time of randomization;
- Known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor;
- Concurrent medical condition with a life expectancy of less than 12 months.
- The patient is unwilling/ not able to return for outpatient clinic at 1 month and 12 months follow-up.
- Currently participating in another trial and not yet at its primary endpoint.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02385279

Principal Investigator: | P. W. Serruys, Prof. MD. | International Center for Circulatory Health, NHLI, Imperial College, London, United Kingdom | |
Principal Investigator: | W Wijns, Prof. MD. | Hartcenter, OLV Aalst, Belgium | |
Principal Investigator: | R. de Winter, Prof. MD. | Academisch Medisch Centrum, Amsterdam, The Netherlands |
Responsible Party: | ECRI bv |
ClinicalTrials.gov Identifier: | NCT02385279 |
Other Study ID Numbers: |
ECRI-005 |
First Posted: | March 11, 2015 Key Record Dates |
Last Update Posted: | December 19, 2020 |
Last Verified: | December 2020 |
CAD ACS All comers PCI |
Coronary Stenosis Coronary Disease Myocardial Ischemia |
Heart Diseases Cardiovascular Diseases Vascular Diseases |